Legacy Education (LGCY) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
14 Jan, 2026Executive summary
Revenue for Q1 FY2025 increased 35.1% year-over-year to $14 million, driven by a 25.4% rise in enrollment and higher margin programs.
Net income rose to $2.1 million, nearly doubling from the prior year, with diluted EPS increasing to $0.21 from $0.11.
Completed IPO, raising between $7.9 million and $11.5 million, and issued additional shares, enhancing capital and growth prospects.
Signed an $8 million acquisition agreement for Contra Costa Medical Career College, expected to close in December 2024, expanding program offerings.
Student population grew 25.4% to 2,539, with new student starts up 23.3% to 773, the highest in company history.
Financial highlights
Q1 FY25 revenue reached $14 million, a $3.6 million increase from Q1 2024, reflecting 35% year-over-year growth.
Adjusted EBITDA was $2.8 million, up from $1.4 million year-over-year, with operating income at $2.7 million and margin improving to 19.1%.
Cash and cash equivalents stood at $21.5 million, with working capital over $23 million at quarter end.
Total stockholders' equity was $32.6 million at quarter end.
Market capitalization at $100.5 million, with 13.1 million diluted shares outstanding as of November 2024.
Outlook and guidance
Positioned for record revenue, starts, student population, and earnings in fiscal 2025, with continued growth expected through organic expansion, new programs, and M&A.
Anticipates closing the Contra Costa acquisition in December 2024, increasing total programs to 47 and enrollment to over 3,000.
Sufficient liquidity to support ongoing operations, planned capex, and M&A activities.
No formal guidance provided, but management expressed confidence in continued strong performance and growth.
M&A opportunities are being explored both within and outside California, with a focus on successful integration of current acquisitions.
Latest events from Legacy Education
- Q2 revenue up 40.7% and net income up 46%, fueled by enrollment and program expansion.LGCY
Q2 202612 Feb 2026 - Achieved 40% revenue growth and 38% enrollment increase, driven by healthcare-focused programs and acquisitions.LGCY
Investor presentation12 Feb 2026 - Q2 FY2025 revenue up 29.2% with record enrollment and expanded healthcare offerings.LGCY
Q2 202516 Dec 2025 - Virtual meeting to elect six directors, ratify auditor, and review governance and compensation.LGCY
Proxy Filing2 Dec 2025 - Annual proxy details voting items and confirms standard shareholder rights.LGCY
Proxy Filing2 Dec 2025 - IPO targets $10.28M for expansion, with strong growth but high regulatory risk.LGCY
Registration Filing29 Nov 2025 - IPO seeks $10.28M to fund growth, with strong financials but high regulatory exposure.LGCY
Registration Filing29 Nov 2025 - IPO seeks up to $11.95M for expansion, with strong growth but high regulatory risk.LGCY
Registration Filing29 Nov 2025 - Strong growth in revenue and enrollment, with IPO funding expansion amid regulatory risks.LGCY
Registration Filing29 Nov 2025